China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)
(Incorporated in Bermuda with limited liability)
(Stock Code: 673)

COMPLETION OF (I) SUBSCRIPTIONS OF NEW SHARES UNDER SPECIFIC MANDATE; AND (II) RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR EVERY TEN (10) SHARES HELD ON THE RECORD DATE

Reference is made to (i) the circular (the "**Circular**") of China Health Group Limited (the "**Company**") dated 31 July 2025 in relation to the Proposal; (ii) the prospectus (the "**Prospectus**") of the Company dated 3 September 2025 in relation to the Rights Issue on the basis of three (3) Rights Shares for every ten (10) Shares held on the Record Date at the Issue Price of HK$0.10 per Rights Share; (iii) the announcement of the Company dated 24 September 2025 in relation to revision of the expected timetable of the Proposal due to bad weather; and (iv) the announcement of the Company dated 3 October 2025 in relation to, among others, the results of the Rights Issue. Capitalised terms used herein shall have the same meanings as those defined in the Circular unless the context otherwise requires.

COMPLETION OF THE SUBSCRIPTIONS AND THE RIGHTS ISSUE

The Board is pleased to announce that completion of the Subscriptions and the Rights Issue took place on 6 October 2025.

The Subscriptions

All the conditions precedent to the Subscriptions have been fulfilled, and 500,000,000 Subscription Shares, 100,000,000 Subscription Shares and 100,000,000 Subscription Shares have been allotted and issued to Subscriber A, Subscriber B and Subscriber C, respectively, in accordance with the terms of the Subscription Agreements.

The Rights Issue

The Rights Issue became unconditional at 4:00 p.m. on Friday, 26 September 2025. The share certificates for the fully-paid Rights Shares have been posted on Monday, 6 October 2025 to those entitled thereto by ordinary post at their own risks.

USE OF PROCEEDS

The gross proceeds raised from the Subscriptions and the Rights Issue were approximately HK$84.7 million and the net proceeds from the Subscriptions and the Rights Issue after deducting the relevant expenses were approximately HK$80.9 million. As disclosed in the Prospectus, the Company intends to apply the net proceeds from the Subscriptions and the Rights Issue as follows:

(a) as to approximately HK$65.3 million for settlement of payables of the Group including: (i) approximately HK$31.2 million for repayment of the Judgment Debt; (ii) approximately HK$15.5 million for settlement of loans (including estimated interest) to the Group which bear interest at 6.5% per annum, are unsecured and repayable on demand; (iii) approximately HK$3.6 million for settlement of overdue salaries of employees of the Group; (iv) approximately HK$5.1 million for the settlement of certain professional fees (save for those relating to the Subscriptions and the Rights Issue); and (v) approximately HK$9.9 million for settlement of overdue Directors remuneration;

(b) as to HK$12 million for repayment of principal amount of the Settlement Note; and

(c) as to the balance amounted to approximately HK$3.6 million as working capital of the Group for payment of daily operating expenses (including staff costs and rental expenses) and settlement of the amount due to suppliers.

EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

Set out below are the shareholding structures of the Company immediately before and after completion of the Proposal:

Shareholders	Immediately before completion of the Proposal		Immediately after completion of the Proposal	
	No. of Shares	*%*	*No. of Shares*	*%*
Mr. Zhang together with his associates and concert parties (including the Underwriter) *(Note 1)*	137,299,400	27.93	178,489,220	13.33
Mr. Wang Jingming (a non-executive Director)	2,850,600	0.58	3,705,780	0.28
Mr. Xing Yong (an executive Director)	139,800	0.03	181,740	0.01
Mr. Ying and his concert parties:				
Mr. Ying and Subscriber A *(Note 2)*	16,211,900	3.30	521,075,470	38.91
Subscriber B	–	–	100,000,000	7.47
Subscriber C	–	–	100,000,000	7.47
Sub-total	16,211,900	3.30	721,075,470	53.85
Placees	–	–	27,803,637	2.08
Other public Shareholders	335,143,063	68.16	407,882,344	30.45
Total	**491,644,763**	**100.00**	**1,339,138,191**	**100.00**

Notes:

1) *Immediately after completion of the Proposal, Mr. Zhang is directly interested in 1,699,620 Shares and indirectly interested in 176,789,600 Shares through the Underwriter, the entire issued share capital of which is owned by Mr. Zhang.*

2) *Immediately after completion of the Proposal, Mr. Ying is directly interested in 21,075,470 Shares and indirectly interested in 500,000,000 Shares through Subscriber A, the entire issued share capital of which is owned by Mr. Ying.*

By order of the Board
China Health Group Limited
Chung Ho
Chief Executive Officer and Executive Director

Hong Kong, 6 October 2025

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (Chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Yang Huimin.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.